Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 229 participants.
Also called NCT04720534
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 229 participants
- Sponsor
- Registry
-
NCT04720534
-
- Other papers using this trial's data
- Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Germany, Hungary, Netherlands, New Zealand, Poland
- Registry status
- Completed
Technical summary
Registry record NCT04720534. Randomized; quadruple masking; primary purpose treatment. Start 2021-05-31 (actual); primary completion 2023-03-09 (actual). Results posted on 2026-03-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
- Acronym
- SHASTA-2
- Condition
- Severe Hypertriglyceridemia
- Intervention (Drug)
- ARO-APOC3
- Intervention (Drug)
- Placebo
- Lead sponsor
- Arrowhead Pharmaceuticals
Record details
- Record id
cardio:ct-nct04720534- Content hash
dc680f9fe156249e0d277496c4dc9dca4eaf2fd20a70a0dc0ee637ffa51923a5